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ABSTRACT 
 
Background 
 
                       Cardiovascular disease is the major cause of mortality and morbidity  
 
in individuals with diabetes. More than 70 % of the deaths in individuals with  
 
diabetes is  accounted  by  the  macrovascular  complications associated with it,  
 
namely- coronary heart disease, peripheral vascular disease and cerebrovascular  
 
accidents . 
 
 
                          Diabetic dyslipidemia  plays an important role in the pathogenesis  
 
of accelerated atherosclerosis. It consists of elevated triglycerides, low HDL  and   
 
increased small dense LDL (sLDL). In the recent times, triglyceride levels have   
 
emerged as an independent risk factor for atherosclerosis. 
 
 
                           Diabetes is predominantly a post prandial metabolic disorder.  
 
Serum  triglycerides generally increase maximally 3-6 hours after a meal, more so  
 
in diabetics. Once postprandial  triglyceridemia occurs, it is further exacerbated by  
 
the next meal. As we stay in a post prandial state for most of the day, measurement  
 
of serum triglycerides in both fasting and  postprandial state may provide a more  
 
reliable estimate of  hypertriglyceridemia  among diabetics. 
 
 
                         As  the  carotid  intima  media  thickness  (CIMT) is a surrogate  
 
marker of  atherosclerosis, to investigate the role of  fasting  and postprandial 
 
hypertriglyceridemia  in early atherosclerosis, there is a need to correlate the  
 
triglyceride levels and carotid intima media thickness values. 
 
 
Objectives: 
 
•  To investigate the extent of association between fasting and postprandial  
 
triglyceride levels and carotid intimal thickness  in patients with type 2 
 
diabetes mellitus. 
 
 
MATERIAL & METHODS: 
 
 
This is a comparative study in which 100 type 2 diabetic patients in the age group  
 
of  35-65 years ,with average duration of diabetes between 1-5 years, are included. 
 
 
STANDARDIZED  MIXED  MEAL  TEST: 
 
Subjects underwent a standardized mixed meal test after an overnight fast. The total  
 
energy content of the meal was 9Kcal/kg, with 20% of energy from fat, 60 % from  
 
carbohydrate,20 % from protein. Blood samples for lipid profile were taken before,  
 
 and 4hrs  after the  standardized meal.  
 
 
Measurement of carotid IMT : 
 
By Doppler studies: Carotid artery Doppler was done by B-mode ultrasound using a  
 
7.5 MHZ transducer . 
Inclusion criteria: 
 
(a) type 2 Diabetes patients 
 
(b) HbA1C< 7% 
 
 
Exclusion criteria: 
 
(a)    Patients receiving lipid lowering agents, thiazides, beta blockers. 
       
(b)    Known cases of hypothyroidism  not  on  thyroxine  replacement  
 
   therapy,  
 
(c)    Patients with chronic complications of diabetes such as nephropathy,  
 
             hepatic disease, current h/o alcoholism & smoking and existing IHD as     
           
             determined by history & ECG 
 
(d) Patients  who had CVD ( by history & clinical examination) 
 
(e) Patients with history/ clinical findings suggestive of familial  
 
hyperlipidemias 
 
                         Patients receiving OHAs, antihypertensives  (ACE inhibitors or AT  
 
II antagonists) and  antiplatelet drugs  were not excluded from the study. 
 
 
STATISTICAL ANALYSIS 
 
                  Data was entered in windows excel format. Frequency tables and  
 
measures of central tendency (mean) and measures of dispersion (Standard  
 
deviation) were obtained by using the statistical package SPSS -20.  
 
RESULTS: 
 
             The study population was divided into 3 groups based on their fasting and  
 
postprandial triglyceride levels. 
 
 
NORMO-NORMAL (NN) GROUP 
 
This group consisted of subjects with normal fasting triglyceride level 
 
(=150 mgs/dl) and normal postprandial triglyceride levels (=200 mgs/dl). 
 
 
NORMO-HYPER (NH) GROUP 
 
This group consisted of subjects with normal fasting triglyceride level 
 
(=150 mgs/dl) and elevated postprandial triglyceride levels (>200 mgs/dl). 
 
 
HYPER – HYPER (HH) GROUP  
 
This group consisted of subjects with elevated fasting  triglyceride  level 
 
(>150mgs/dl) and elevated postprandial triglyceride levels (>200 mgs/dl). 
 
 
Fasting & postprandial triglycerides and carotid intimal thickness in NN, NH & HH   
 
groups: 
 
 NN group NH group  HH group 
Fasting 
triglycerides(mg/dl) 
107.29± 20.69 132.57±7.52 230.13±48.96 
Postprandial 
triglycerides(mg/dl) 
146.35±27.75 276.10±72.84 333.29±87.38 
CIMT (mm ) 0.96±0.30 1.85±0.47 1.80±0.49 
 CONCLUSION: 
 
                     The conclusion of the present study is that there is a correlation  
 
between  postprandial hypertriglyceridemia and carotid intima- media  
 
thickness (CIMT)  
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   INTRODUCTION 
 
 
 
 
INTRODUCTION 
 
 
                        Diabetes is a group of metabolic disorders that shares the  
 
genotype of  hyperglycemia
(1)
. The prevalence of diabetes in the world is  
 
increasing to the extent  that, now, it has attained the status of an epidemic. It is  
 
estimated that the global burden of diabetes in going to increase to a 360 million  
 
level by 2030
(1)
 . 
 
 
                       Cardiovascular disease is the major cause of  morbidity and  
 
mortality in diabetics. 70% of the deaths in these patients are due to  
 
macrovascular complications attributed to it. The contribution of diabetes in  
 
causing accelerated atherosclerosis and therefore premature vascular disease  
 
had  led to its labelling as a coronary risk equivalent. It increases the risk of  
 
coronary artery disease by 2-3 fold 
(2)
. 
 
                      Diabetic dyslipidemia is the major factor contributing to this  
 
premature atherosclerosis. It has been recognised that dyslipidemia increases the  
 
risk of macrovascular complications independent of other  risk factors often  
 
seen in them like hypertension. obesity, smoking etc. 
 
 
                      The components of this dyslipidemia are elevated triglycerides,  
reduced HDL and elevated small dense LDL 
(3,4) 
. Initial studies showed  that   
LDL  was responsible for these early atherosclerotic changes but now the role  
of elevated triglycerides has been recognised. Some studies  showed elevated  
 
triglycerides as an independent risk factor for premature vascular disease
(5)
 . It  
 
was seen that coronary event increased in patients with  fasting triglyceride   
 
(fTG) values >1.13mmol/l 
(6)
.  
        
                       Many studies have shown a correlation between fasting  
 
triglycerides and increased coronary risk but they are few studies on the  role of  
 
post prandial triglycerides. 
 
 
                       Diabetes is a predominantly post prandial metabolic disorder.  
 
Serum triglycerides are seen to rise 3-6 hours after a meal , more so in diabetics. 
 
Once post prandial triglyceridemia occurs it is only exacerbated by the next  
 
meal.Since we stay in post prandial state through most of the day, the post prandial 
triglyceridemia is sustained. Therefore our circulation is exposed to the elevated 
triglycerides for a major part of the day. Therefore, postprandial triglycerides may 
have a greater role in the atherosclerotic process than the fasting triglycerides. 
                       
                     Patients with early atherosclerotic changes are generally  
 
asymptomatic. Only when the vascular occlusion reaches a significant  
 
percentage do they become symptomatic. Assessing carotid intimal thickness  
 
using carotid Doppler has been shown as a non-invasive and quantitative  
 
method to detect these early changes
(7).
 
                           
The carotid intima-media thickness (CIMT) has been shown to increase in    
 
patients with fasting and postprandial hypertriglyceridemia 
(8)
 . So  
 
to investigate the role of  hypertriglyceridemia in early atherosclerosis there is a  
 
need to correlate between fasting and postprandial triglyceride levels and  
 
carotid intima-media thickness values. 
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AIMS AND OBJECTIVES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 Estimation of fasting and postprandial triglyceride levels in patients  with  
 
type 2 diabetes mellitus. 
 
 Estimation of carotid intima media thickness by Doppler ultrasonography 
 
 To investigate the extent of association between fasting and  
 
postprandial triglyceride levels and carotid intimal thickness  in patients  
 
with type 2 diabetes mellitus 
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ATHEROSCLEROSIS 
 
 
It is derived from Greek where “athere” means gruel and “skleros” means hard. 
It is one of the patterns of  arteriosclerosis
 (9) 
 . 
 
ARTERIOSCLEROSIS: It is a generic term reflecting arterial wall thickening 
and loss of elasticity . It means “hardening of  the arteries”. 
3 patterns exist 
(9)
 : 
 Arteriosclerosis: It affects small arteries and arterioles. It has two anatomical 
variants: hyaline & hyperplastic 
 Monckeberg medial sclerosis: occurs in muscular arteries in persons older 
than 50 years of age. Usually clinically insignificant 
 Atherosclerosis: characterised by atheroma. It is the clinically important 
pattern. 
                    This phenomenon  of  occurrence of  arterial hardening  with age is as 
old as Egyptian mummies. 
                    The first description of this phenomenon in the modern era was made 
by Leonardo da Vinci (1449- 1519). 
                    Among the various manifestation of atherosclerosis, coronary artery 
disease is the most important and dreadful, and along with aortic and carotid artery 
disease, is responsible for most of  the mortality and morbidity in the world. The 
prevalence of coronary heart disease is an indirect indicator  of  the burden of 
atherosclerosis. 
                   Initially, it was most prevalent in the developed countries but  in the 
recent times there is an increasing trend in the developing countries too. 
 
PATHOGENESIS: 
                  The characteristic lesions are  atheromas. These lesions form in the 
intima and as the atherosclerosis progresses they begin to encroach upon the 
lumen.               
               The early phase was dominated by two hypotheses: 
 Humoral theory:  proposed by Karl Von Rokintansky .It focused on the role 
of formation and healing of thrombi in the development of atherosclerosis. 
 Cellular theory: proposed by Rudolf Virchow. It focused cellular 
proliferation in the arterial intima following its infiltration by components 
derived from the plasma 
             The theory which dominated the early phase of modern times is:  
Response-to-injury hypothesis 
(10).  
  
             The term “atherosclerosis” was   first introduced by Felix Marchand in 
1904. He postulated that narrowing of the arterial lumen is caused by 
atherosclerosis
(3)
 . 
             Atherosclerosis was induced experimentally by  A.I. Ignatowski in 1908 
by feeding cholesterol rich food  thereby showing  a relationship between both
(11).
 
               In 1910, Adolf  Windaus showed that atheromatous lesions contained 6 
times as much free cholesterol and 20 times as much esterified cholesterol as a 
normal arterial wall 
(11)
 
              In 1913, Nikolai N. Anichkov showed that cholesterol alone caused the 
atheromatous changes in the vascular wall
(11)
. 
                    The theory accepted nowadays is a modification  of  the above theory-  
Response-to-retention hypothesis
(12)  
. 
MECHANISMS: 
 ENDOTHELIAL DYSFUNCTION: 
                                  The initial theories hypothesized endothelial injury/ 
dysfunction as the earliest abnormality to occur during  the pathogenesis of 
atherosclerosis 
(13,14) 
 . Endothelium, under normal conditions, elaborates nitric 
oxide and thrombolytic factors which maintain a free flow in the vessel lumen. 
Endothelial  dysfunction/ injury  was said to alter these properties and predispose 
the arteries  to atherosclerosis. 
                  Exposure to injurious stimuli like smoking, hypertension and 
hyperlipidemia could lead to increased endothelial permeability, enhanced 
leukocyte adhesion and altered gene expression. Inflammatory cytokines (e.g. 
TNF) may play an role in the expression of  pro- atherogenic  genes. Two of the 
causes which were said to be most important in the development of  endothelial 
dysfunction are:                    
 Lipids: both hyperlipidemia and excess of  altered  lipoproteins  are 
implicated as the cause of endothelial dysfunction which lead to increased 
transudation of  lipoproteins mainly LDL, as well as lipoprotein (a) 
chylomicrons, and VLDL into the arterial intima. 
 Hemodynamic disturbances: Plaques tend to occur at the sites of  turbulent 
flow patterns like vessel branching points  and  ostia of the exiting vessels. 
Also, various studies demonstrated that , in regions with  laminar flow, there 
is an elaboration of  genes whose products are atheroprotective . 
However, the histopathological evaluation of  vascular endothelium in various 
experimental studies showed that the earliest lesions occur in vessels whose 
endothelium is morphologically intact. Subsequently many studies were conducted 
in animal models which have demonstrated that the rate of lipoprotein entry into 
atherosclerosis-susceptible sites could be either increased 
(15,16)
 or decreased 
(17)
, 
suggesting a nonessential role for alterations in endothelial permeability . 
 LIPIDS: 
                   Hyperlipidemia plays a contributory role in the pathogenesis of 
atherosclerosis. Chronic hyperlipidemia increases oxygen free radical production 
which can cause local tissue injury and  accelerate the rate of  nitric oxide decay, 
thereby, reducing its vasodilator activity and hence causing endothelial 
dysfunction. 
                   Lipoproteins accumulate, either in the presence or absence of  
endothelial dysfunction, within the intima. These lipids are  then bound to 
proteoglycans which prevent its efflux from the intima
(18)
. The next and most 
important step in the pathogenesis of atherosclerosis is oxidation of  lipoproteins 
by the local  macrophages or endothelial cells. Lipid oxidation occurs normally in 
the cells but these oxidised LDL particles are blocked by the plasma proteins
(19)
 
and albumin or rapidly cleared by the liver
(20)
 after they appear in the circulation. 
But in the arterial intima they are well protected from the plasma and hence more 
susceptible to oxidation.  
 INFLAMMATION: 
                    Oxidized LDL stimulates the endothelial cells, smooth muscle cells
(21)
 
and macrophages to release  chemokines  and  growth factors that  cause increased 
monocyte recruitment into the lesions. 
                    Dysfunctional endothelial cells express adhesion molecules vascular 
cell adhesion molecules 1 (VCAM- 1), in particular, that enhance the binding of 
leukocytes especially monocytes
(22)
. Under the influence of locally produced 
chemokines these cells then migrate into the intima.                     
                   Monocytes transform into macrophages and engulf  lipoproteins 
including oxidized LDL. Oxidized LDL then augments macrophage activation and 
cytokine production which further increases leukocyte adhesion and chemokine 
production. The macrophages then transform into foam cells. 
                 
 SMOOTH MUSCLE PROLIFERATION: 
                  Smooth muscle proliferation and extracellular matrix deposition  in the 
intima lead to the final maturation of the plaque. 
 
 
MORPHOLOGY:  
FATTY STREAKS
(9)
: 
                 Earliest lesions in atherosclerosis. Composed of lipid-filled foamy 
macrophages. Appear as flat yellow spots which later coalesce to form  elongated 
streaks. They do not cause any alteration in the flow. Aortas of infants can also 
exhibit these lesions but not all fatty steaks develop into advanced lesions. Fatty 
streaks begin to form in the coronary circulation in adolescence, at the same 
anatomic sites that later develop plaques. 
FIBRO FATTY PLAQUE
(9)
: 
                 Have three principle components: 
1) Cells, including smooth muscle cells, macrophages, and T cells; 
2) ECM, including collagen, elastic fibres, and proteoglycans; and 
3) Intracellular and extracellular lipid- form about 40 % of  volume of the 
plaque. 
                   There is a superficial cap of smooth muscle cells and relatively dense 
collagen. Beneath and to the side of the cap is a more cellular area containing 
macrophages, T cells, and smooth muscle cells. Deep to the cap is a necrotic core, 
containing lipid (cholesterol and cholesterol esters), dead cell debris, foam cells, 
fibrin. There is peripheral neovascularization. 
                    These plaques impinge on the lumen of the artery. The order of 
involvement of vessels is lower abdominal aorta, coronary arteries, popliteal 
arteries, internal carotid and then circle of  Willis. 
ADVANCED (COMPLICATED) PLAQUE
(9)
: 
1) Calcification is the most common complication. Calcium deposition may be  
patchy or extensive. 
2) Rupture, ulceration, or erosion: exposes the blood  to the  highly 
thrombogenic substances thereby inducing thrombosis. 
3) Haemorrhage into the plaque. 
4) Atheroembolism: due to discharge of atherosclerotic debris into the blood 
stream following plaque rupture. 
5) Aneurysm formation: due to pressure atrophy of the underlying media. 
 
VULNERABLE PLAQUE: 
                  These are plaques which have high probability of  undergoing 
thrombotic complications and rapid progression
(23)
. The concept of vulnerable 
plaque was proposed by Muller more than 15 years ago
(24)
. The first histologic 
description was described later and defined as a fibroatheroma with a fibrous cap 
65µm or thinner. These generally favour proximal arteries. They have a lipid- rich 
necrotic core and a thin fibrous cap infiltrated by macrophages. 
LIPOPROTEINS: 
                   The major lipids in the plasma, particularly triglycerides and 
cholesterol, are transported bound to water soluble molecules designated as 
lipoproteins. 
COMPOSITION OF LIPOPROTEINS IN PLASMA: 
                   The  main classes of  lipoprotein, which can be identified by 
ultracentrifugation
(25)
, are : 
1) chylomicrons, 
2) very low-density lipoproteins,  
3) low-density lipoproteins and  
4) High density lipoproteins 
LIPPROTEIN CLASS MAJOR COMPONENTS 
Chylomicrons Triglycerides  
VLDL i. Triglycerides 
ii. Cholesterol esters 
iii. Phospholipids 
LDL i. Cholesterol esters 
ii. Phospholipids 
HDL i. Cholesterol esters 
ii. Phospholipids 
 
 
 
LIPOPROTEIN  METABOLISM 
It is divided into three processes: 
i. Exogenous pathway 
ii. Endogenous pathway 
iii. Reverse cholesterol transport 
 
EXOGENOUS  PATHWAY 
 
                   This consists of the metabolism of  dietary lipids. Most of the dietary 
triglycerides as well as cholesterol are absorbed in the small intestine. They are 
hydrolyzed and later reesterified in the intestinal mucosa to form triglycerides. Apo 
B48 and Apo A apoproteins are later incorporated into them to form chylomicrons  
which, after assembly, enter the intestinal lymphatics. From the lymphatics, they  
enter the circulation where they acquire apoproteins C and E mainly from HDL 
particles
(26)
. 
                  In the plasma, the triglycerides in the chylomicrons are acted upon by 
the  enzyme lipoprotein lipase, which is located on the endothelium of capillary 
vessels in muscle and adipose tissue, and rapidly hydrolyzed  to free fatty acids and 
glycerol. Apoprotein CII
(27)
 and insulin are activators of this enzyme, whereas 
apoprotein CIII is an inhibitor. After the removal of  triglycerides, the apoproteins 
Apo A and C are transferred to HDL. The  residual particles of  this process are  
known as chylomicron remnants .Specific receptor-mediated interaction in the 
liver, which involves the recognition of  apoprotein E, is required for their 
clearance from the circulation. 
 
ENDOGENOUS PATHWAY 
                   It consists of  transport of  endogenous triglycerides formed in the 
liver. VLDL acts as the carrier for these triglycerides. They are formed by the 
assembly of  triacylglycerol and cholesterol with apolipoprotein  B-100 and small 
amounts of Apo C and Apo E. 
                   VLDL particles acquire the  apolipoprotein C-II  and apolipoprotein E 
from HDL particles. Once the apolipoproteins are incorporated into it, the nascent 
VLDL particle is considered mature. 
                   Once VLDL particles enter the circulation they are acted upon by 
lipoprotein lipase which is expressed on the endothelial cells. Lipoprotein lipase is 
activated by Apolipoprotein C-II
(27)
 and upon activation it causes hydrolysis of the 
VLDL particle leading to the release of free fatty acids and glycerol. These 
products are available for utilisation by the peripheral tissues, principally adipose 
tissue and muscle. The VLDL particles, after hydrolysis, are designated as VLDL 
remnants or intermediate density lipoproteins (IDLs). VLDL remnants are the 
ready to enter the circulation and can either be hydrolysed by the action of hepatic 
lipase or can be absorbed by the liver via an interaction  between apolipoprotein E 
and the VLDL remnant receptor
(28)
. 
                   Next step in the metabolism of  endogenous lipoproteins is the 
formation of  low density lipoproteins (LDL). These are cholesterol-rich IDL 
remnants which are formed by the  hydrolysis of  VLDL remnants/IDL by thereby 
releasing free fatty acids and glycerol. The cholesterol content is mainly in the 
form of esters. 
                     LDL enters the circulation and, with the interaction between apoB-
100  or  Apo E on its surface and LDL receptor on the target tissue, is taken up for 
further metabolism . LDL undergoes hydrolysis in the lysosomes after its uptake 
via endocytosis, releasing  unesterified cholesterol and amino acids (formed by the 
breakdown of protein components). 
                 The unesterified cholesterol plays a major role in the regulation of 
cholesterol metabolism. It accumulates in the cytoplasm after crossing the 
lysosomal membrane where it downregulates  the expression of  the LDL receptor 
thereby lowering  the rate of cholesterol uptake and also, reduces the  rate of 
cholesterol synthesis by suppressing  the activity of  HMG Co A reductase.  Also, a 
point noteworthy is the role of LDL receptor in cholesterol metabolism. Interaction 
between apoprotein E of  IDL and this receptor particles limits the formation of  
LDL. 
REVERSE CHOLESTEROL TRANSPORT 
(25)
 
 
 
                  The hepatic output of  cholesterol  greatly exceeds tissue requirements. 
Therefore, the majority of cholesterol transported to cells via LDL is returned to 
the liver for elimination in bile, conversion into bile salts or reassembly into 
lipoproteins. This process is called reverse cholesterol transport. 
                    Reverse cholesterol transport is less well understood than the 
exogenous and endogenous pathways, but HDL appears to play a major role. HDL 
contains the enzyme lecithin cholesterol acyl transferase, which catalyzes the 
formation of cholesterol ester from free cholesterol. The precursors of mature HDL 
molecules, secreted by the liver and intestine, are composed largely of protein 
(apoproteins AI and AII) and phospholipid. It is suggested that through the activity 
of lecithin cholesterol acyl transferase, the particles acquire the bulk of their lipid 
during circulation through the vascular bed. Cholesterol ester formed in this way 
may be delivered directly to the liver but is usually transferred to VLDL and LDL 
and then to the liver via the LDL receptor. 
 
 
ADULT   TREATMENT  PANEL III GUIDELINES(29) 
 
METABOLIC SYNDROME: 
 
                     It is characterized by a constellation of metabolic risk factors in  
 
one individual. The root causes of the metabolic syndrome are  
 
overweight/obesity, physical inactivity, and genetic factors. 
        
                    The metabolic syndrome is closely associated  with a generalized  
 
metabolic disorder called insulin resistance, in which tissue responsiveness to  
 
the normal action of insulin is impaired. Some individuals are genetically  
 
predisposed to insulin resistance; in these persons, acquired factors (excess  
 
body fat and physical inactivity) elicit insulin resistance and the metabolic  
 
syndrome. 
 
                   Most persons with insulin resistance have abdominal obesity and   
 
clinical studies have noted a high correlation between abdominal obesity and  
 
the risk factors characteristic of the metabolic syndrome. 
 
 
                       Risk factors associated with metabolic syndrome: 
 
● Abdominal obesity 
 
● Atherogenic dyslipidemia 
 
● Raised blood pressure 
 
● Insulin resistance ± glucose intolerance 
 
● Prothrombotic state 
 
● Proinflammatory state 
 
                    Because of the high degree of association of these risk factors in  
 
persons with the metabolic syndrome, it has proven difficult to dissect the  
 
individual contributions of each factor to CHD risk.  
 
 
                   However, there is little doubt that this syndrome taken in aggregate  
 
enhances  the risk for CHD at any given LDL-cholesterol level. In addition, the  
 
resistance accompanying the metabolic syndrome is one of the underlying  
 
causes of type 2 diabetes. 
 
 
DIAGNOSIS OF METABOLIC SYNDROME: 
 
                  There are no well-accepted criteria for the diagnosis of the metabolic  
 
syndrome. For present   purposes, the metabolic syndrome is identified by the 
 
presence  of  three or more of the  following components: 
 
RISK FACTOR  
 
DEFINING LEVEL 
Abdominal Obesity 
Men 
Women 
 
Waist Circumference 
>102 cm 
>88 cm 
 
Triglycerides ≥150 mg/dL 
 
HDL cholesterol 
Men 
Women 
 
<40 mg/dL 
<50 mg/dL 
 
Blood pressure  
 
≥130/85 mmHg 
Fasting glucose  ≥110 mg/dL 
 
 
                   Closely associated with abdominal obesity is an elevation of serum 
 
triglycerides. The elevation can be either borderline high (150-199 mg/dL) or  
 
high(≥200 mg/dL). A higher triglyceride level is usually accompanied by lower  
 
HDL cholesterol concentrations. HDL-cholesterol levels <40 mg/dL occur  
 
commonly in men with insulin resistance. For women, HDL cholesterol <50  
 
mg/dL counts as one indicator in the diagnosis of the metabolic syndrome.  
 
 
                   Impaired fasting glucose (110–125 mg/dL) usually is an indicator of  
 
insulin resistance and is frequently accompanied by other metabolic risk factors. 
 
Type 2 diabetes is the epitome of the metabolic syndrome. Other components of  
 the metabolic syndrome (insulin resistance, pro-inflammatory state, and  
 
prothrombotic state) cannot be identified by routine clinical evaluation. 
 
 
 ATP III CLASSIFICATION OF  TOTAL CHOLESTEROL: 
 
Total Cholesterol Category  
 
ATP III Levels (mg/dL) 
Desirable  <200 
Borderline High  200-239 
High  ≥ 240 
 
 
 
 ATP III CLASSIFICATION OF  LDL CHOLESTEROL: 
 
LDL Cholesterol Category  
 
ATP III Levels (mg/dL) 
Optimal  <100 
Near optimal/above optima  100-129 
Borderline High  130-159 
High  160 – 189 
Very High  ≥190 
 
                    In population studies, the serum total cholesterol is a good  
 
surrogate for LDL- cholesterol levels. The Framingham Heart Study, the  
 
Multiple Risk Factor Intervention Trial (MRFIT), and the Lipid Research  
 
Clinics (LRC) trial a direct relationship between levels of LDL cholesterol (or  
 
total cholesterol) and the rate of new-onset CHD in men and women who were  
 
initially free of CHD. 
 
                    Any LDL cholesterol above100 mg/dL appears to be atherogenic. 
 ATP III CLASSIFICATION OF  HDL CHOLESTEROL: 
 
 
HDL Cholesterol Category  
 
ATP III Levels (mg/dL) 
Low HDL cholesterol <40 mg/dL 
High HDL cholesterol ≥60 mg/dL 
 
 
 ATP III CLASSIFICATION OF  TRIGLYCERIDES: 
 
Triglyceride Category  
 
ATP III Levels (mg/dl) 
Normal triglycerides  <150 mg/dL 
Borderline-high triglycerides  150-199 mg/dL 
High triglycerides  200-499 mg/dL 
Very high triglycerides  ≥ 500 mg/dL 
 
                        The finding of elevated serum triglycerides helps to identify  
 
persons who are at risk and who need intervention for risk reduction. In  
 
addition, when triglyceride levels are ≥ 200 mg/dL, the presence of increased  
 
quantities atherogenic remnant lipoproteins can heighten CHD risk.  
 
NON HDL CHOLESTEROL: 
                    
                  The sum of  VLDL+LDL cholesterol is called non-HDL cholesterol. 
 
Since VLDL cholesterol is highly correlated with atherogenic remnant  
 
lipoproteins, it can reasonably  be combined with LDL cholesterol to enhance  
 
risk prediction when serum triglycerides are high. 
 
                   Non-HDL cholesterol includes all lipoproteins that contain Apo B. 
 
Serum total Apo B also has been shown to have a strong predictive 
 power for severity of coronary atherosclerosis and CHD events. 
 
Because of the high correlation between non-HDL cholesterol and 
 
apolipoprotein B levels, non-HDL cholesterol represents an acceptable 
 
surrogate marker for total apolipoprotein B in routine clinical practice. 
 
                    In most persons with triglyceride levels <200 mg/dL, VLDL  
 
is not substantially elevated, and further, non-HDL cholesterol correlates highly  
 
with LDL cholesterol; therefore, adding VLDL cholesterol to LDL cholesterol  
 
at lower triglyceride levels would be expected to provide little additional power  
 
to predict CHD. 
 
                   When triglyceride levels are≥200 mg/dL, VLDL cholesterol levels     
 
are distinctly raised, and LDL-cholesterol concentrations are less well correlated  
 
with VLDL and LDL (non-HDL) cholesterol levels; consequently, LDL  
 
cholesterol alone inadequately defines the risk associated with atherogenic  
 
lipoproteins. In the presence of high serum triglycerides, non-HDL cholesterol  
 
therefore will better represent the concentrations of all atherogenic lipoproteins  
 
than will LDL cholesterol alone.  
          
                 When triglyceride levels become very high (e.g., ≥500 mg/dL) some  
 
of the cholesterol in TGRLP resides in nonatherogenic forms of larger VLDL  
 
and chylomicrons, and non- HDL cholesterol may be less reliable as a predictor  
 
of  CHD risk. 
DIABETIC DYSLIPIDEMIA 
 
                    Hyperlipidemia refers to the conditions which lead to an increase in  
 
the concentrations of  lipoproteins in the plasma . It could be caused either due   
 
increased production of lipoproteins or decreased clearance or both. 
 
It could be primary or secondary. 
 
 Primary hyperlipidemia: occurs due to genetic defects that lead to  
 
abnormal lipoprotein metabolism. 
 
 Secondary hyperlipidemia: it consists of other metabolic conditions  
 
which cause abnormalities in lipoprotein metabolism indirectly. 
 
Causes: are divided based on the class of  lipoprotein that is elevated  
 
predominantly (Refer Table) 
(25)
 
 
Type of 
Disorder 
MAJOR PLASMA LIPID ABNORMALITY 
 Increased Cholesterol Increased Cholesterol and 
Triglyceride 
Increased Triglyceride 
Primary 
 
 Familial 
hypercholesterolemia  
 
 Familial defective 
apo-B100  
 
 Polygenic 
hypercholesterolemia  
 
 
 Familial combined 
hyperlipidemia  
 
 Type III 
hyperlipoproteinemia 
(dysbetalipoproteinemia)  
 
 
 Familial 
hypertriglyceridemia  
 
 LPL deficiency  
 
 Apo-CII deficiency  
 
 Sporadic 
hypertriglyceridemia  
 
Secondary 
 
 Hypothyroidism  
 
 Nephrotic syndrome  
 
 
 Hypothyroidism  
 
 Nephrotic syndrome  
 
 Diabetes mellitus  
 
 
 Diabetes mellitus  
 
 Alcoholic 
hyperlipidemia  
 
 Estrogen therapy  
 
 
                     The term  dyslipidemia is often applied to patients who are not  
 
hypercholesterolemic according to existing NCEP guidelines
(30)
. 
 
 
                  In type 1 diabetes, pathophysiology involves the presence of  insulin  
 
deficiency and poor glycemic control. These factors lead to impairment  in  
 
lipoprotein lipase activity  and enhance lipolysis at the same time which  
 
ultimately is responsible for the elevation of the plasma levels of triglycerides  
 
and Apo-B–containing  lipoproteins. The lipid abnormalities in type 1 diabetes  
 
are reversible with insulin therapy. 
 
                   In type 2 diabetes, insulin resistance has a central role in the  
 
development of  dyslipidemia. Relative insulin deficiency plays a  
 
contributory role. Hyperlipidemia caused due to insulin resistance is  
 
accompanied by many other metabolic abnormalities which  include obesity,  
 
hypertension, and hyperglycemia which are referred to as the metabolic  
 
syndrome. 
 
                      Diabetic dyslipidemia consists of : 
 
1) elevated triglycerides,  
 
2) elevated small dense LDL,  
 
3) reduced HDL, and 
 
4) Post prandial lipemia. 
 
 
HYPERTRIGLYCERIDEMIA: 
 
                 It is the most frequently detected abnormality in lipoprotein metabolism 
in patients with uncontrolled diabetes. In the U.K. Prospective Diabetes 
Study(UKPDS), the serum triglyceride levels of  3,041 newly detected  type 2 
diabetic patients was found to be 2.46 mmol/l 
(31)
. In a study conducted in 2005 in 
newly recruited defense personnel, it was demonstrated that, raised triglyceride 
levels was a strong predictor of diabetes in the future in patients with fasting blood 
glucose levels of 4.5–5.0 mmol/l (32). 
                  
    Mechanism:                 
                 Dyslipidemia in diabetes is characterized by elevated postprandial 
triglyceride-rich lipoproteins (TRLs). 
                The important steps in the metabolism of  TRLs in normal individuals 
are: 
(i) the assembly and secretion of  VLDL particles,  
(ii) the hydrolysis of triglycerides in TRLs by LPL,  
(iii) the direct uptake of  TRL remnants in the liver, and  
(iv) the flux of  Apo B 100 through VLDL-IDL-LDL delipidation 
cascade in circulation. 
 
DEFECTS  IN VLDL METABOLISM IN DIABETES: 
The major defects of triglyceride metabolism in diabetes are: 
 Increased endogenous triglyceride and VLDL production. 
 Decreased VLDL clearance 
 C-apolipoprotein defects 
 
 Increased endogenous triglyceride production:  
                  There is increased flux of free fatty acids from peripheries to the liver 
secondary to decrease in lipoprotein lipase activity both in adipose tissue and in the 
muscles
(33,34)
. There is also an increased production of apolipoprotein B by the liver 
as in all the insulin resistance states
(35)
. All these factors drive the reaction in the 
direction of  increased VLDL and triglyceride production by the liver
(33)
 and hence 
increased formation of triglyceride- rich lipoproteins (TRLs). 
 
 Decreased VLDL clearance: 
                   It involves LPL, the activity of which is often reduced in Type 2 
diabetics
(34)
.  
                   The second mechanism is diminished hepatic uptake of  VLDL. 
Among the apoproteins present in VLDL, apoprotein C III is the most abundant. It 
plays an important role in VLDL metabolism by affecting it at various levels
(36,37)
.  
 Apo CIII a direct inhibitor of  LPL activity(38). 
 TRLs which contain high concentrations of  Apo CIII  undergo catabolism at 
slow rates
(39,40)
. 
 It impairs the hepatic uptake of remnant particles by interfering with the Apo 
E-mediated receptor binding 
(41,42)
. 
 
                  In insulin deficient and resistant states, the VLDL subfraction which is 
produced predominantly is the larger buoyant, triglyceride enriched VLDL1 
particle. These larger VLDL 1 particles are released only in the fasting state in 
normal individuals but not in the postprandial phase as, in the postprandial state, 
there is a chylomicron flux from the intestine. But insulin resistance alters the 
balance and leads to excessive postprandial VLDL1 production. 
                The overall effect is the production of  large buoyant VLDL 1 particles 
which are highly triglyceride enriched and undergo very slow clearance from the 
circulation. 
                  
ELEVATED SMALL DENSE LDL (sLDL): 
 
                       sLDL particles are the variants of  LDL and have a high 
concentration of triglycerides. These are formed due to exchange of cholesterol 
esters and triglycerides between LDL and TRLs. VLDL1 is the precursor of  
sLDL. Excessive VLDL1 in the circulation along with its diminished clearance 
rate favors the formation of   sLDL. Also, hepatic lipase activity is enhanced in 
diabetics which accelerates the formation of  LDL from  IDL
(43,44)
. sLDL 
concentration is increased in type2 diabetics irrespective of  the LDL levels.  
 
REDUCED  HDL  LEVELS: 
                        This occurs due to enhanced clearance of HDL from the circulation. 
Elevated triglycerides in the circulation lead to enrichment of  HDL particles with 
triglycerides owing to the exchange of triglycerides between TRLs and HDL. This 
leads to increased clearance of  HDL by the action of hepatic lipase as triglyceride 
enrichments makes HDL a good substrate to it.   
                       In addition, glucose and insulin regulate certain steps in HDL 
metabolism by regulating the expression of  some proteins like ABCA-1 and 
PLTP
(45,46)
. 
 
POSTPRANDIAL LIPEMIA: 
 
Mechanism:  
I. Impaired lipolysis of   VLDL1: in the postprandial state, the metabolism of  
VLDL is affected due to the flux of chylomicrons into the circulation as the 
triglycerides that are contained in the larger lipoproteins are metabolized 
faster than the smaller ones. Along with this, insulin resistance leads to 
ineffective suppression of  VLDL1 production by insulin. As a result, the 
lipolysis of  VLDL1 is further impaired leading to its delayed clearance from 
the circulation. 
II. Impaired clearance of  VLDL remnants by LDL receptors in the liver.   
III. Impaired LPL activity:  as LPL activity is regulated by insulin(34).          
 
 
ATHEROGENICITY OF DIABETIC DYSLIPIDEMIA: 
 
                 Increased VLDL1 acts as a precursor for the production of  sLDL, plays 
a role in the triglyceride enrichment of  HDL and also in postprandial lipemia. 
                Elevated sLDL is highly atherogenic because arterial intima is highly 
permeable to it
(47)
and also its delayed clearance leads to the exposure of the arterial 
intima  to sLDL for prolonged periods.  
               Lipoproteins and their remnants are shown to interact with coagulation 
factors
(48)
. 
 
 
 
 
 
 
EVALUATION OF CAROTID ARTERY INTIMA- 
 
MEDIA THICKNESS  BY DOPPLER ULTRASOUND 
 
                     Atherosclerosis is an inevitable accompaniment of ageing. Its rate of 
development depends on several well-known risk factors that include hypertension, 
smoking, dyslipidemia as well as the glycaemic status. As several primary and 
secondary prevention methods like life style and pharmacological interventions, 
are available for attenuating the development of atherosclerosis, it is of  prime 
importance to identify at an early stage, the subjects who at risk of developing 
accelerated atherosclerosis. 
                      Increased carotid intima media thickness is seen to be associated  
with increased risk of cardiovascular and cerebrovascular disease
(49)
. Patients  
 
with early atherosclerotic changes are generally  asymptomatic. Only when the  
 
luminal obstruction occurs to a significant percentage do they become  
 
symptomatic. Assessing carotid intimal thickness using carotid Doppler has  
 
been shown as a non-invasive and quantitative method to detect these early  
 
changes
(7)
. 
 
                   Measurement of intima-media thickness of extra cranial carotid arteries 
by B mode ultrasound imaging has been shown to correlate well with 
histopathological picture. 
                      Atherosclerosis is a disease affecting the arterial wall. The initial 
changes are noticeable only in the wall. As the atherosclerotic changes progress, 
there is a resultant dilatation of the affected artery
(50)
 .This compensatory change 
takes place so as to maintain the size of the arterial lumen leading to a very 
minimal reduction in the lumen size when compared to a healthy artery. In fact, the 
decline in the luminal size is noticeable only when the stenosis has progressed to at 
least 40 %. Therefore, angiography, as a tool, is inadequate to study the early 
atherosclerotic changes as it can only measure luminal encroachment. During the 
early 1980s,  B mode ultrasonography emerged as an alternative to angiography to 
quantify early atherosclerotic changes in the carotid artery 
(51,52)
.  
                      The advantage of  B mode ultrasound to angiography lies in the cost 
effectiveness and its capability and precision in diagnosing early intimal changes. 
Also, serial measurements can be undertaken to monitor progression or regression 
of the atherosclerotic changes. 
                   The CIMT measurements were defined as the linear distance between 
the two ultrasonic interfaces making the boundaries between adventitia and media 
and lumen and intima. The intima-media thickness is at present the best-studied 
sonographic marker for early atherosclerosis. A thickening of intima-media 
complex not only reflects local alterations but also corresponds to generalized 
atherosclerosis. 
                Patient was placed in supine position with neck slightly extended. 
Scanning of  both side arteries was performed in anteroposterior projections.  
Scanning of  extracranial common carotid or internal carotid arteries in neck is 
performed bilaterally according to evading edge of second echogenic line. The 
lumen intimal interface is represented by the first line and the second line 
represents the tunica adventitia. At each longitudinal projections, three 
determinations of IMT are conducted. The first one at the site of greatest thickness 
and the other two at a point one centimetre downstream and one centimetre 
upstream from the site of greatest thickness respectively. The three values are then 
averaged. The normal intimal + medial thickness of common carotid artery as 
evaluated by B-mode ultrasound imaging was 0.74 ± 0.14mm 
(53)
. 
 
 
 
Measurement of CIMT: three 
measurements taken- one at the CCA 
bifurcation & one each 1cm proximal & 
distal to the bifurcation. 
  
 
 
Carotid Doppler showing intima-media thickness. CIMT in this 
image is 0.98mm. Three readings are taken and the average CIMT 
calculated. 
 
  
 
 
Carotid Doppler showing increased intima-media thickness 
with plaque. CIMT in this image is 2.3mm. Three readings 
are taken and the average CIMT calculated. 
  
 Carotid Doppler showing increased intima-media thickness. CIMT in this image 
is 1.6mm. Three readings are taken and the average CIMT calculated. 
  
 
 
Carotid Doppler showing increased intima-media thickness with plaque. CIMT in 
this image is 2.3mm. Three readings are taken and the average CIMT calculated. 
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MATERIAL AND METHODS 
 
 
                  This study was done at Govt. Stanley medical college, Chennai  
 
between July 2010 – August 2011. 
 
 
STUDY DESIGN  & PATIENT SELECTION: 
      
                  This is a comparative study in which 100 type 2 diabetic patients in  
 
the age group of  35-65 years ,with average duration of diabetes between 1-5  
 
years, are included. 
 
Inclusion criteria: 
 
1. Type 2 Diabetes patients 
 
2. HbA1C< 7% 
 
Exclusion criteria: 
 
1. Patients receiving lipid lowering agents, thiazides, beta blockers. 
 
2. Known cases of  hypothyroidism  not  on thyroxine  replacement therapy, 
 
3. Patients with chronic complications of diabetes such as nephropathy,   
 
hepatic disease, current h/o alcoholism & smoking and existing IHD as     
 
          determined by history & ECG 
 
4. Patients  who had CVD ( by history & clinical examination) 
 
5. Patients with history/ clinical findings suggestive of familial  
 
Hyperlipidemias. 
                         Patients receiving OHAs, antihypertensives  (ACE inhibitors or  
 
AT II antagonists) and  antiplatelets were not excluded from the study. 
 
 
All the patients were subjected to the following investigations before entering  
 
the study:  
 
 Hemoglobin 
 
 TC,DC 
 
 ESR 
 
 RBS,FBS, PPBS 
 
 Blood urea 
 
 Serum creatinine 
 
 Urine- microscopy, sugar, albumin 
 
 24 hour urine protein 
 
 HbA1C 
 
 ECG 
 
 
STANDARDIZED  MIXED  MEAL  TEST: 
 
                    Subjects underwent a standardized mixed meal test after an  
 
overnight fast. The total energy content of the meal was 9Kcal/kg, with 20% of  
 
energy from fat, 60 % from carbohydrate,20 % from protein. Blood samples for  
 
lipid profile were taken before and  4hrs  after the  standardized meal. Total  
 cholesterol, fasting and postprandial triglycerides, HDL were measured by  
 
standard laboratory technique. LDL cholesterol was calculated with  
 
Friedewald‟s formula-LDL Cholesterol = Total Cholesterol – (HDL  
 
+Triglycerides/5). 
 
Measurement of carotid IMT : 
 
                 By Doppler studies: Carotid artery Doppler was done by B-mode  
 
ultrasound using a 7.5 MHZ transducer. 
 
 
STATISTICAL ANALYSIS 
 
                Data was entered in windows excel format. Frequency tables and  
 
measures of central tendency (mean) and measures of dispersion (Standard  
 
deviation) were obtained by using the statistical package SPSS -20. Variation  
 
between the three group means was studied using analysis of variants  
 
(ANOVA) and test statistic F values were obtained with appropriate degrees of  
 
freedom and p values were obtained with appropriate level of significance. To  
 
compare means of two groups students „t‟ test was used with appropriate  
 
degrees of freedom and levels of significance. 
 
 
 
 
 
  
 
 
 
 
 
OBSERVATION &    
                            RESULTS 
 
 
 
 
 
 
 
 
Table 1 
DISTRIBUTION OF SUBJECTS BY AGE GROUP 
 
 
Age group (in 
years) 
Subjects (NN 
Group) 
Subjects (NH 
Group) 
Subjects (HH 
Group) 
TOTAL 
No % No % No %  
35-40 7 14.58 4 19 3 9.67 14 
41-50 11 22.91 9 42.85 8 25.80 28 
51-60 23 47.91 5 23.80 14 45.16 42 
>60 7 14.58 3 14.28 6 19.35 16 
TOTAL 48  21  31   
 
 
 
 
 
 
 
                                                                         
         
                          
 The mean age of the patients in the NN group was 50.98 ± 8.52. 
 
 The mean age of the patients in the NH was 48.76 ± 8.53. 
 
 The mean age of the patients in the HH group was  52.77 ± 8.04. 
 
The „p‟ value was 0.102 which implies that the subjects in various age groups   
 
where distributed equally among the three groups (NN, NH and HH). 
 NN NH HH 
Range 36-65 36-64 36-65 
Mean 50.98 48.76 52.77 
SD 8.52 8.53 8.04 
                 F=1.532                     p=0.102 
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 Table 2 
DISTRIBUTION OF SUBJECTS BY SEX 
 
 
 
 
       SEX 
Subjects (NN 
Group) 
Subjects (NH 
Group) 
Subjects (HH 
Group) 
No % No % No % 
 
      Male 
 
24 
 
50 
 
13 
 
62 
 
17 
 
55 
 
      Female 
 
24 
 
50 
 
 8 
 
38 
 
14 
 
45 
 
     TOTAL 
 
48 
  
21 
  
31 
 
 
 
 
Among  the  total  of  100 patients, 54 were males (54%) and 46 were females 
(46%). 
 
               In the NN group, 24 were males (50%) and 24 were females (50%). 
 
               In the NH group, 13 were males (62%) and 8 were females (38%). 
 
               In the HH group, 17 were males (55%) and  14 were females (45%).
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Table 3 
 
DISTRIBUTION OF SUBJECTS BY TREATMENT TAKEN FOR 
DIABETES 
 
 
 
 
 In NN group, 34(70.83%) patients were on OHA, 11(22.91%) patients on  
insulin and 3(6.25%) patients on both OHA and insulin. 
 
 
 In NH group,18 (85.71%) patients were on OHA, 1(4.76%) patient was  
 
on  insulin and  2(9.52%) patients on both OHA & insulin. 
 
 
 In HH group , 22(70.96%)patients were on OHA, 6(19.35%) patients  
 
were on insulin and 3(9.67%) patients on both OHA and insulin 
 
 
 
In all the three groups, majority of the subjects were on OHAs and a 
 
smaller percentage were on insulin. 
 
 
 
 
 
Drugs 
Subjects (NN Group) Subjects (NH Group) Subjects (HH Group) 
No % No % No % 
OHA 34 70.83 18 85.71 22 70.96 
Insulin 11 22.91 1 4.76 6 19.35 
OHA+  
Insulin 
3 6.25 2 9.52 3 9.67 
Table 4 
 
DISTRIBUTION OF SUBJECTS BY RISK FACTORS 
 
 
Hypertension  Subjects ( NN  
Group) 
Subjects (NH 
Group) 
Subjects (HH 
Group) 
No % No % No % 
Present  9 18.75 5 23.80 7 22.58 
Absent  39 81.25 16 76.19 24 77.41 
 
 
 
 In NN group,  9 were  hypertensives ( 18.75%). 
 
 In NH group,  5 were  hypertensives ( 23.80%). 
 
 In HH group,  7 were  hypertensives ( 22.58%). 
 
 
The distribution of  hypertensives among all the three groups was equal. 
 
 
 
 
 
 
 
 
 
Table 5 
DISTRIBUTION OF SUBJECTS BY 
SYSTOLIC BLOOD PRESSURE IN DIFFERENT GROUPS 
 
 
Systolic BP 
(in mm Hg) 
Subjects (NN 
Group) 
Subjects (NH 
Group) 
Subjects (HH 
Group) 
 No      
               
% No % No % 
<140 44 91.66 18 85.71 27 87.09 
140-159 4 8.33 2 9.52 4 12.90 
≥160 -  1 4.76 -  
TOTAL 48  21  31  
 
            
 NN NH HH 
Range  110-150 110-160 110-150 
Mean 124.38 126.76 126.65 
SD 9.89 12.60 9.32 
 
                        F= 0.627 
                                                                              
p= 0.537                                                     
 
 
 The mean systolic BP in NN group is 124.38 ± 9.89. 
 
 The mean systolic BP in NH group is 126.76 ± 12.60. 
 
 The mean systolic BP in HH group is 126.65 ± 9.32. 
 
                 The distribution of  systolic  BP among all the three groups was equal. p  
 
value was 0.537 which shows that  the groups were similar to each other in the 
 
distribution of  systolic BP. 
 
Table 6 
DISTRIBUTION OF SUBJECTS BY 
DIASTOLIC BLOOD PRESSURE IN DIFFERENT GROUPS 
 
 
Diastolic BP 
(in mm Hg) 
Subjects (NN 
Group) 
Subjects (NH 
Group) 
Subjects (HH 
Group) 
 No      
               
% No % No % 
<90 44 91.66 18 85.71 27 87.09 
90-99 3 8.33 1 4.76 2 6.45 
≥100 1  2 9.52 2 6.45 
TOTAL 48  21  31  
 
 
 NN NH HH 
Range  70-106 68-100 70-100 
Mean 78.29 78.86 79.94 
SD 6.82 8.93 7.40 
                        F= 0.455 p= 0.636 
 
 
 The mean diastolic BP in NN group is 78.29 ± 6.82 
 
 The mean diastolic BP in NH group is 78.86 ± 8.93 
 
 The mean diastolic BP in HH group is 79.94 ± 7.40 
 
 
The distribution of  diastolic BP among all the three groups was equal. p value  
 
was 0.636 which shows that  the groups were similar to each other in the  
 
distribution of  diastolic BP. 
Table 7 
DISTRIBUTION OF SUBJECTS BY BMI IN DIFFERENT GROUPS 
 
BMI 
(in kg/m
2
) 
Subjects (NN 
Group) 
Subjects (NH 
Group) 
Subjects (HH 
Group) 
No % No % No % 
15-20 10 20.83 3 14.28 4 12.90 
21-25 26 54.16 13 61.90 18 58.06 
26-30 8 16.66 3 14.28 6 19.35 
31-35 3 6.25 1 4.76 3 9.67 
>35 1 2.08 1 4.76 -  
TOTAL 48  21  31  
 
 
 NN NH HH 
Range 18.14-36.44 19.14-35.56 18.73-33.06 
Mean 23.38 24.19 24.45 
SD 4.17 4.24 3.92 
                        F= 0.718 
 
                         p=0.490 
 
 In the NN group, the mean BMI was 23.38 ± 4.17. 
  
 In the NH group, the mean BMI was 24.19 ± 4.24. 
 
 In the HH group, the mean BMI was 24.45 ± 3.92. 
 
              The distribution of BMI among all the three groups was equal. p value  
 
was  0.490 which shows that  the groups were similar to each other in the  
 
distribution of  BMI. 
  
 
 
 
 
 
 
0
20
40
60
80
100
120
140
NN
NH
NH
124.38 
126.76 126.65 
78.29 
78.86 79.94 
B
L
O
O
D
 P
R
E
S
S
U
R
E
 
GROUPS 
DISTRIBUTION OF SYSTOLIC AND DIASTOLIC BP IN DIFFERENT 
GROUPS 
systolic BP
Diastolic BP
22.8
23
23.2
23.4
23.6
23.8
24
24.2
24.4
NN
NH
HH
23.38 
24.19 24.25 
B
M
I 
Groups 
DISTRIBTION OF BMI IN DIFFERENT GROUPS 
 Table 8 
DISTRIBUTION OF SUBJECTS BY SERUM TOTAL CHOLESTEROL IN 
DIFFERENT GROUPS 
 
Serum cholesterol 
(in mg/dl) 
Subjects (NN 
Group) 
Subjects (NH 
Group) 
Subjects (HH 
Group) 
No 
 
% No % No % 
≤200 48 100 19 90.47 27 87.09 
>200 - - 2 9.52 4 12.90 
TOTAL 48  21  31  
 
 
 
 
           NN         NH HH 
Range      98-166   116-231         110-256 
Mean      141.19    162.67         176.42 
SD       20.00     30.46         30.69 
 
 
      
 
 The mean serum total cholesterol in the NN group was 141.19 ± 20. 
 
 The mean serum total cholesterol in the NH group was 162.67 ± 30.46. 
 
 The mean serum total cholesterol in the HH group was 176.42 ± 30.69.  
 
 
 
 
Table  9 
 
DISTRIBUTION OF SUBJECTS BY SERUM  LDL IN DIFFERENT 
GROUPS 
 
 
Serum LDL 
cholesterol (in 
mg/dl) 
Subjects (NN 
Group) 
Subjects (NH 
Group) 
Subjects (HH 
Group) 
No 
 
% No % No % 
<100 30 
 
62.5 12 57.14 20 64.51 
100-130 18 37.5 6 28.57 7 22.58 
>130 -  3 14.28 4 12.90 
TOTAL 48  21  31  
 
 
 NN NH HH 
Range 47-114 58-158 53-180 
Mean 85.98 100.14 97.84 
SD 19.12 26.98 31.32 
 
 
 
 
 The mean serum LDL cholesterol in the NN group was 85.98 ± 19.12 
 
 The mean serum LDL cholesterol in the NH group was 100.14 ± 26.98 
 
 The mean serum LDL cholesterol in the HH group was 97.84 ± 31.32  
 
 
Table 10 
DISTRIBUTION OF SUBJECTS BY SERUM HDL IN DIFFERENT 
GROUPS 
 
Serum HDL 
cholesterol (in 
mg/dl) 
Subjects (NN 
Group) 
Subjects (NH 
Group) 
Subjects (HH 
Group) 
No 
 
% No % No % 
≤40 45 93.75 19 90.47 28 90.32 
>40 3 6.25 2 9.52 3 9.67 
TOTAL 48  21  31  
 
 
 
              NN             NH HH 
Range         33.13-48           28-52 18-45 
Mean            40.57           35.43 32.87 
SD            5.23             6.33 6.30 
 
 
 
 
 The mean serum HDL cholesterol in the NN group was 40.57 ± 5.23 
 
  The mean serum HDL cholesterol in the NH group was 35.43 ± 6.33 
 
 The mean serum HDL cholesterol in the HH group was 32.87 ± 6.30 
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 Table 11 
DISTRIBUTION OF SUBJECTS BY SERUM FASTING TRIGLYCERIDES 
IN DIFFERENT GROUPS 
 
 
Fasting 
Triglycerides 
(mg/dl) 
Subjects(NN 
Group) 
Subjects(NH 
Group) 
Subjects (HH 
Group) 
No % No % No % 
<150 48 100 21 100 -  
150-249 -  -  18 58.06 
250-349 -  -  13 41.93 
≥350 -  -    
TOTAL 48  21  31  
 
 
 NN NH HH 
Range 60-145 120-145 158-327 
Mean  107.29 132.57 230.13 
SD 20.69 7.52 48.96 
 
 
 
 
 
 The mean serum fasting triglyceride in the NN group was 107.29 ± 20.69. 
 
 The mean serum fasting triglyceride in the NH group was 132.57 ± 7.52. 
 
 The mean serum fasting triglyceride in the HH group was 230.13 ± 48.96. 
 
 
 
 
 
 Table 12 
DISTRIBUTION OF SUBJECTS BY SERUM POSTPRANDIAL 
TRIGLYCERIDES IN DIFFERENT GROUPS 
 
 
Postprandial 
Triglycerides 
(mg/dl) 
Subjects(NN 
Group) 
Subjects(NH 
Group) 
Subjects (HH 
Group) 
No % No % No % 
<200 48 100 -  -  
200-299 -  16 76.19 12 38.70 
300-399 -  3 14.28 14 45.16 
≥400 -  2 9.52 5 16.12 
TOTAL 48  21  31  
 
 
 
 NN NH HH 
Range 93-198 210-501 202-522 
            Mean 146.35 276.10 333.29 
SD 27.75 72.84 87.38 
 
 
 
 
 The mean serum postprandial triglyceride in the NN group was 146.35 ± 
27.75 
 
 The mean serum postprandial triglyceride in the NH group was 276.10 ± 
72.84 
 
 The mean serum postprandial triglyceride in the HH group was 333.29 ± 
87.38 
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 Table 13 
DISTRIBUTION OF SUBJECTS BY CIMT IN DIFFERENT GROUPS 
 
 
CIMT 
(in mm) 
Subjects (NN 
Group) 
Subjects( NH 
Group) 
Subjects (HH 
Group) 
No 
 
% No % No % 
0.5-1 32 66.66 -  1 3.22 
1.1-1.5 14 29.16 6 28.57 7 22.58 
1.6-2 2 4.16 8 38.09 17 54.83 
2.1-2.5 -  6 28.57 3 9.67 
2.6-3 -  1 4.76 2 6.45 
>3 -  -  1 3.22 
TOTAL 48  21  31  
 
 
 
 
 NN NH HH 
Range 0.60-1.60 0.99-2.71 0.88-3.13 
Mean 0.96 1.85 1.80 
SD 0.30 0.47 0.49 
 
 
 
 In the NN group the mean carotid IMT was 0.96 ± 0.30.  
 
 In the NH group the mean carotid IMT was 1.85 ± 0.47.  
 
 In the HH group the mean carotid IMT was 1.80 ± 0.49. 
 Table 14 
DISTRIBUTION OF FASTING AND POSTPRANDIAL TRIGLYCERIDES 
WITH CIMT 
 
 
Triglycerides (mg/dl) Number CIMT  p  value F 
value 
 
Fasting 
triglycerides 
<150 69 1.23 ± 0.54  
 
  0.004 
 
2.418 
 
150-249 18 1.78 ± 0.51 
250-349 13 1.83 ± 0.59 
 
Postprandial 
triglycerides 
<200 48 0.96 ± 0.30  
 
  <0.001 
 
3.313 
 
200-299 28 1.74 ± 0.39 
300-399 17 1.86 ± 0.65 
≥ 400 7 2.03 ±0.18 
 
 
Fasting triglycerides: 
 
 The mean CIMT of subjects with fasting triglycerides < 150 was 1.23± 0.54. 
                                                                     
 The mean CIMT of subjects with fasting triglycerides 150-249  
 
                                                               was1.78± 0.51. 
 
 The mean CIMT of subjects with fasting triglycerides 250-349                        
                                                                              was1.83± 0.59. 
            
 
 
Postprandial triglycerides:               
         
 The mean CIMT of subjects with postprandial triglycerides < 200 was  
 
                                                                                                          0.96±0.30. 
 
 
 The mean CIMT of subjects with postprandial triglycerides 200-299 was  
 
                                                                                                         1.74±0.39. 
 
 
 The mean CIMT of subjects with postprandial triglycerides300-399 was  
 
                                                                                                         1.86±0.65. 
 
 
 The mean CIMT of subjects with postprandial triglycerides ≥400 was  
  
                                                                                                        2.03±0.18. 
 
 
                Depicted below are two scatter diagrams with regression lines where 
fasting and postprandial triglycerides are correlated with CIMT respectively.  
               The model R
2 
(the coefficient of determination) for fasting triglycerides is 
0.254 which along with a significant p value of  0.004 shows that about 25% of the 
variation in CIMT can be explained by the level of  fasting triglycerides. 
                The model R
2 
(the coefficient of determination) for postprandial 
triglycerides is 0.442 which along with the p value of <0.001 (extremely 
significant)  shows that about 44% variation in CIMT can be explained by the level 
of postprandial triglycerides. 
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Table 15 
Univariate linear regression 
Dependant 
variables 
Independent 
variables 
R
2
  p value 
CIMT fTG 0.254 0.004 
CIMT ppTG 0.442 <0.001 
ppTG fTG 0.445 0.001 
 
Table 16 
Multivariate linear regression correlation  with CIMT 
 
Multivariate linear regression correlating  with CIMT 
Variables  B T P R
2 
fTG -0.001 -0.737 0.463 
0.445 
ppTG 0.004 5.771 <0.001 
 
 
 The above table shows a multivariate linear regression model where both 
fasting and postprandial triglycerides are correlated with CIMT. The overall model 
R
2 
(the coefficient of determination) is 0.445 which is not much higher compared 
to the univariate linear regression including only ppTG (0.442). The p value for 
ppTG is significant in the model (<0.05) whereas the p value for fTG (>0.05) was 
not significant implying that only ppTG is significantly correlating with CIMT and 
the initial univariate plots are confounded by the fact that both fTG and ppTG are 
correlating strongly between themselves.  
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 Table 17 
DISTRIBUTION OF BMI WITH CIMT 
 
 
        BMI (in kg/m
2
)
 
No of Subjects CIMT P value 
       <18-24.9            74 1.38 ± 0.57  
0.567         25-29.9            17 1.62 ± 0.65 
        30-35             7 1.16 ± 0.61 
        ≥35             2 1.41 ± 0.014 
 
 
 The mean CIMT in subjects with BMI  <18-24.9 is  1.38± 0.57. 
 
 The mean CIMT in subjects with BMI    25-29.9 is  1.62± 0.65. 
 
 The mean CIMT in subjects with BMI    30-35    is  1.16± 0.61. 
 
 The mean CIMT in subjects with BMI       ≥35    is  1.41± 0.014. 
 
 
 
                 The p value was 0.567 was which not significant thereby showing that 
there was no statistically significant difference in the distribution of BMI among 
the three groups. 
 
 
 
 
 
 
 
                  DISTRIBUTION OF BMI WITH CIMT 
TABLE 18 
SUMMARY 
Difference in variables among the NN, NH, and HH groups 
 
 
Sl No. Variables NN NH HH 
1 Age 50.98±8.52 48.76±8.53 52.77±8.04 
2 Sex (M/F) 24/24 13/8 17/14 
3 Treatment(O/I/O+I) 34/11/3 18/1/2 22/6/3 
4 BMI 23.38 ± 4.17 24.19 ± 4.24 24.45 ± 3.92 
5 No of hypertensives 9 5 7 
6 Systolic BP 124.38±9.89 126.76±12.06 126.65±9.32 
7 Diastolic BP 78.29 ± 6.82 78.86 ± 8.93 79.94 ± 7.40 
8 Total Cholesterol 141.19±20 162.67±30.41 176.42±30.69 
9 LDL Cholesterol 85.98±19.12 100.41±26.98 97.84±31.32 
 
10    HDL Cholesterol 40.57±5.23 35.43±6.33 32.87±6.30 
11 Fasting Triglycerides 107.29±20.69 132.57±7.52 230.13±48.96 
12 Postprandial Triglycerides 146.35±27.75 276.10±72.84 333.29 ± 87.38 
13            CIMT 0.96±0.30 1.85±0.47 1.80 ± 0.49 
TABLE 19 
RELATIONSHIP OF SELECTED VARIABLES WITH CAROTID IMT 
 
 
 
                    The p values of all the above  variables were not significant 
suggesting that all the above variables were distributed equally among all the 
three  groups.
    
 
VARIABLES p VALUE 
1 BMI (in kg/m
2
)
 
0.567 
2 SYSTOLIC BP 0.521 
3 DIASTOLIC BP 0.517 
4 TOTAL CHOLESTEROL 0.797 
5 LDL CHOLESTEROL 0.640 
  
 
      DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
AGE: 
                 The mean age group of  the patients in the present study was 50.98 ± 
8.52, 48.76± 8.53 and 52.77 ± 8.04 in the NN, NH and HH groups respectively. 
                        
       Snichi Teno et al:  
                   The mean age group in their study, on the evaluation of postprandial 
hypertriglyceridemia with carotid intima-media thickness in type 2 diabetes 
mellitus, was 52.5±6.2, 54.7 ±9.1 and 54.9 ±7.7 years in the NN, NH and HH 
groups respectively
(3)
.
  
 
RISK FACTORS /HYPERTENSION: 
                 Among a total no of 100 pateints, 21 were hypertensives. The number of  
hypertensives in NN,NH and HH were 9,5 and 7 respectively. 
                 The mean systolic BP in NN,NH and HH groups was 124.38±6.77, 
126.76±12.60 and 126.65±9.32 mm Hg respectively. 
                 The mean diastolic BP in the NN, NH and HH groups was 
78.29±6.82,78.86±8.9379.94±7.40 mm Hg respectively. 
                  
        Snichi Teno et al:  
                  In their study, the mean systolic B.P. in the NN, NH and HH group was 
130 ± 16, 136 ± 16 and 139 ± 16 mmHg respectively. The mean diastolic B.P. in 
the NN, NH and HH group was 77 ± 8.5, 83 ± 7 and 80 ± 8 mm Hg respectively. 
 
BODY MASS INDEX (BMI): 
              The mean BMI in the present study was 23.38 ± 4.17,24.19± 4.24 and  
24.45± 3.92 kg/m
2
 in the NN, NH and HH group respectively. 
              Snichi Teno et al:  
              In their study, the mean BMI in the NN, NH and HH group was 23.5 ± 
3.1, 25.9 ± 4.1 and 25 ± 2.5 kg/m
2 
respectively. 
 
LIPID PROFILE: 
Serum Total Cholesterol: 
              The mean serum total cholesterol in the NN, NH and HH group was 
141.19 ± 20, 162.67 ± 30.4 and 176.42± 30.69 mg/dl respectively. Total 
cholesterol is higher in both NH and HH group than the NN group 
Serum LDL: 
               The mean serum LDL was 85.98 ± 19.12, 100.14 ± 26.98 and 97.84± 
31.32  mg/dl in the NN, NH and HH group respectively.  
Serum HDL:  
              The mean serum HDL was 29.96 ± 8.17, 34.50 ± 5.48 and 32.54 ± 6.28 
mg/dl in the NN, NH and HH group respectively. 
Serum Fasting Triglycerides: 
                  The mean serum fasting triglyceride were 107.29 ± 26.09, 132.57 ± 
7.52 and 230.16 ± 48.96 mg/dl in the NN, NH and HH group respectively. 
Serum postprandial Triglycerides:  
                   The mean serum postprandial triglycerides were 146.35 ± 35.06, 
276.10± 72.84 and 333.29 ± 87.38 mg/dl in the NN, NH and HH group 
respectively. 
 
Snichi Teno et al: 
                     The mean serum total cholesterol in their study,in the NN,NH and HH 
group was 194.9 ± 28.0, 220.7 ± 23.4 and 228.4 ± 44.2 mg/dl respectively. 
                    The mean serum HDL in the NN, NH and HH group was 53 ± 13.5, 
59.6 ± 11.9 and 49.9 ± 13.1 mg/dl respectively. 
                    The mean serum LDL in the NN, NH and HH group was 119.9 ± 
25.1,137.7 ± 23.9 and 121.4 ± 36.7 mg/dl respectively. 
                    The mean serum fasting triglycerides in the NN, NH and HH group 
were 111.1 ± 39.9, 125.3 ± 21.3 and 270.2 ± 110.2 mg/dl respectively. 
                    The mean serum postprandial triglycerides in the NN, NH and HH 
group were 145.5 ± 44.4, 263.1± 42.6 and 391.9 ± 237.3 mg/dl respectively. 
Carotid Intima-Media thickness:  
                   In the present study,the mean CIMT in the NN, NH and HH group 
were 0.96 ± 0.30, 1.85 ± 0.47 and 1.80 ± 0.49 mm respectively.                    Snichi 
Teno et al: 
                     In their study, the mean CIMT in the NN, NH and HH group were 
0.73± 0.13, 0.86 ± 0.13 and 0.85 ± 0.12 mm respectively. 
Frederick Karpe et al:  
 
                     It was proved in their study, on  the magnitude of alimentary lipemia 
in relation to intima-media thickness of the common carotid artery in middle aged 
men, that postprandial plasma triglycerides, in particular, those measured after 3-6 
hrs after intake of test meal correlated positively with CIMT (p<0.05) 
V. Mohan et al: 
                     It was shown in their study,on intimal-medial thickness of carotid 
artery in the south Indian diabetic and non-diabetics, that the mean carotid intimal-
medial thickness of  diabetic subjects was significantly higher than those of non-
diabetic subjects (0.95 ± 0.31 mm Vs 0.74 ± 0.14 mm with p < 0.001). 
 
 
RELATIONSHIP  OF  THE  VARIABLES  WITH  CIMT: 
Blood  pressure, Total cholesterol, LDL: 
           The p value for the above was not significant as noted before 
suggesting that all the three variables were distributed equally among the three 
groups. 
Fasting and postprandial triglycerides: 
                  Both fasting and postprandial triglycerides showed significant p values 
(0.004 for fTG  and <0.001 for ppTG) suggesting a correlation between them and 
CIMT. Even the univariate regresssion analysis showed similar results. But, the 
multivariate regression analysis showed that the only ppTG is significantly 
correlating with CIMT and the initial univariate plots are confounded by the fact 
that both fTG and ppTG are correlating strongly between themselves.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
    CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 
 
 
1) Carotid intima-media thickness is higher in people with postprandial 
hypertriglyceridemia despite normal levels of fasting triglycerides. 
2) Postprandial triglyceride levels correlate better with carotid intima- media 
thickness when compared to fasting triglyceride levels and hence can predict 
early atherosclerosis. 
3) Postprandial hypertriglyceridemia can be labelled as an independent 
predictor of accelerated atherosclerosis in diabetics.  
4) In diabetics, postprandial triglycerides should be measured in addition to 
fasting triglycerides. 
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        ANNEXURE 
 
 
 
 
 
 
 
 
 
 
 
 
  
 PROFORMA 
 
ASSOCIATION BETWEEN FASTING AND POSTPRANDIAL  
TRIGLYCERIDE LEVELS AND CAROTID INTIMA-MEDIA THICKNESS  
IN TYPE 2 DIABETES PATIENTS 
 
 
NAME AGE SEX 
OCCCUPATION ADDRESS EDUCATIONAL 
STATUS 
TELEPHONE NO   
 
 
Duration  of   diabetes: 
 
 
 
Past history: 
 
h/o HTN/ IHD/ CVA/ liver diseases/ hypothyroidism 
 
 
Drug history: 
 Insulin/ OHA 
 Lipid lowering agents 
 Thiazides 
 Beta blockers  
 Thyroxine 
 ACE inhibitors  
 AT II antagonists 
 Antiplatelets 
 
 
Personal history: 
 
                   Alcoholism: 
 
smoker/ ex-smoker: 
 
 
EXAMINATION: 
 
1. General physical examination: 
 
2. Height: 
 
3. Weight: 
 
4. BMI: 
 
5. Vitals: 
 
                 Pulse: 
 
BP: 
 
INVESTIGATIONS: 
 
i. Complete Blood Picture: 
Hb:                                                                ESR: 
TC:                                                                DC: 
ii. ECG in all leads: 
iii. Chest X-ray:                 
iv. RBS: 
v. FBS: 
vi. PPBS: 
vii. HBA1C: 
viii. Blood Urea: 
ix. Serum Creatinine: 
x. Urine: Albumin          :             
a. Sugar              : 
b. Microscopy     : 
xi. 24 Hour Urine Protein: 
xii. Lipid profile: 
Total Cholesterol  
HDL  
LDL  
VLDL  
Triglycerides Fasting 
 
 
Postprandial 
 
 
 
 
 
xiii. Carotid Doppler : 
 
                 CIMT: 
 
                           Right:                                                               Left: 
 
               Right Side                 Left Side 
 S mm S/D mm P/I mm S mm S/D mm P/I mm 
CCA       
ECA       
ICA       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 
 
 
 
 
 
 
 
S.No Age Sex Dur OHA Ins SHT SBP DBP Ht Wt BMI Urea Cr TC HDL LDL VLDL fTG ppTG CIMT
1 45 M 2 y N 120 80 172 62 21.29 36 1.1 100 35 64 17 85 134 0.94
2 52 F 2 y y Y 130 80 156 72 29.59 23 8 164 42 108 14 72 184 1.6
3 36 F 3 y N 130 80 160 50 19.53 32 0.8 114 32 58 32 120 198 1.6
4 52 M 3 y N 110 70 172 90 29.05 34 0.7 164 35 108 21 107 125 0.66
5 65 M 4 y Y 130 70 166 62 22.49 27 0.8 129 28 77 24 121 131 0.98
6 60 F 4 y Y 140 90 155 47 19.56 39 0.9 176 40 90 46 232 304 0.88
7 46 M 5 y N 130 74 160 54 21.09 34 1.1 143 28 89 26 130 290 2.33
8 61 F 2 y N 120 80 150 50 22.22 26 1.2 164 30 105 29 145 170 1.46
9 46 M 3 y N 126 76 165 58 21.3 23 0.8 164 35 90 39 195 289 1.65
10 62 M 4 y N 118 70 150 65 28.89 34 0.8 136 22 53 61 327 397 2.6
11 53 M 2 y Y 150 100 152 45 19.48 37 0.7 162 35 94 33 167 234 1.55
12 54 F 2 y y N 120 70 150 82 36.44 29 1.2 161 30 109 24 110 143 1.4
13 55 F 2 y Y 140 90 158 60 24.03 30 1.1 150 32 101 17 86 106 0.65
14 57 M 2 y N 116 70 155 52 21.64 33 0.9 175 43 79 53 267 522 1.99
15 43 M 5 y N 124 68 160 49 19.14 32 0.8 125 30 71 24 126 242 2.12
16 58 F 1 y N 130 80 160 60 23.44 32 0.9 221 33 148 40 187 202 1.19
17 38 F 1 y N 136 74 156 52 21.37 23 0.8 154 35 92 24 136 174 0.85
18 44 F 2 y N 120 80 160 58 22.65 28 0.7 155 34 62 79 296 511 1.83
19 39 M 1 y Y 130 86 150 48 21.33 29 1.1 157 41 89 27 135 174 0.85
20 48 M 2 y N 120 74 166 75 27.21 23 1.2 256 34 180 44 220 304 2.33
  
21 36 M 1 y  N 120 76 170 70 24.22 32 1.3 180 36 96 54 270 425 1.92 
22 36 M 2 y  N 110 80 165 85 31.22 36 0.8 126 36 70 24 99 128 0.61 
23 39 F 4 y  N 126 74 153 45 19.22 35 0.9 125 30 71 24 132 242 2.12 
24 41 M 4 y  N 120 80 160 60 23.44 32 0.7 197 37 132 28 140 501 2.19 
25 43 M 2 y  N 130 80 162 62 23.62 24 0.8 129 28 84 17 86 96 1.2 
26 47 F 2 y  Y 140 100 155 45 18.73 27 0.8 162 35 95 32 158 226 1.61 
27 47 F 2  y N 130 84 155 46 19.14 28 0.7 152 30 103 19 93 129 1.1 
28 48 F 2 y  N 110 72 157 50 20.28 36 0.9 146 36 84 28 130 170 1.1 
29 52 M 2  y Y 130 80 170 84 29.06 24 0.8 167 22 88 56 282 323 1.9 
30 57 M 2 y  Y 120 80 166 80 29.03 28 0.8 164 39 92 33 120 236 2.04 
31 56 M 2 y  N 120 80 162 64 24.38 28 0.9 191 40 126 35 125 433 2.39 
32 56 M 1 y  N 120 84 160 55 21.48 31 0.9 98 30 51 17 86 109 0.65 
33 53 F 2 y  N 124 80 160 58 22.66 29 1 180 30 124 32 128 240 1.47 
34 58 F 2 y  N 120 76 152 68 29.43 28 1.1 166 39 94 33 120 180 1.1 
35 57 F 1  y N 130 82 158 61 24.43 25 0.8 186 31 100 55 276 364 1.1 
36 53 F 2 y  N 120 70 150 50 22.22 28 1.1 113 36 52 25 99 121 1.39 
37 51 F 5 y  N 132 80 152 69 29.86 38 0.7 172 30 108 43 162 315 3.13 
38 62 M 1 y  N 126 76 170 60 20.76 36 1.2 129 28 77 24 121 131 0.98 
39 63 M 2 y  N 110 70 160 68 26.56 32 1.2 127 28 82 17 84 96 1.19 
40 62 F 2 y  N 120 80 155 58 24.14 30 1.1 169 22 90 56 282 323 1.9 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
41 36 M 2 y N 110 80 152 48 20.78 30 0.9 140 37 79 28 120 180 0.8
42 38 F 1 y N 110 74 156 48 19.72 39 0.8 143 36 87 20 99 126 0.75
43 39 F 2 y N 120 78 150 44 19.55 32 0.7 158 35 90 33 167 234 1.62
44 42 M 2 y N 126 76 166 50 18.14 35 1.2 110 28 58 24 99 128 0.64
45 42 M 3 y N 138 80 170 62 21.45 36 1 178 45 80 53 265 516 1.96
46 44 M 2 y Y 126 86 165 58 21.3 32 0.9 142 28 87 27 135 295 2.34
47 48 F 1 y N 120 76 155 70 31.11 25 0.7 188 33 100 54 272 370 1.12
48 50 F 2 y N 120 80 154 69 29.09 28 0.8 167 35 104 30 140 220 1.4
49 58 F 3 y Y 150 90 154 66 27.82 29 0.7 162 37 104 21 106 128 0.66
50 52 F 2 y y Y 120 80 155 53 22.06 25 0.7 166 34 110 22 109 185 0.7
51 52 F 2 y N 130 84 154 62 26.14 27 0.8 156 28 101 27 134 174 1.23
52 55 F 2 y N 120 76 156 60 24.65 23 0.7 162 36 109 17 84 144 0.68
53 54 F 2 y N 124 70 152 72 31.16 34 0.8 130 36 73 25 99 130 0.6
54 57 M 4 y N 118 70 170 66 22.83 30 1 110 18 59 33 167 220 1.82
55 58 M 1 y N 124 80 170 60 20.76 34 1.1 166 36 92 38 191 288 1.64
56 60 M 2 y N 120 80 160 59 23.04 35 0.8 112 38 54 24 98 132 1.38
57 59 M 1 y N 128 76 170 61 21.1 35 0.7 130 30 76 24 122 139 0.96
58 64 M 1 y y N 130 80 158 62 24.83 32 0.7 189 34 117 37 187 280 1.38
59 63 M 3 y N 120 80 156 58 23.83 28 0.7 234 35 162 41 192 306 2.34
60 61 F 1 y N 120 78 160 57 22.26 35 0.7 146 31 74 28 139 210 1.14
 61 37 M 1 y  N 120 70 160 50 19.53 29 0.9 118 34 58 26 128 220 1.59 
62 38 M 1 y  Y 138 90 160 55 21.48 30 0.7 129 26 57 23 227 293 1.99 
63 42 F 2 y  N 124 74 155 45 18.73 28 0.8 152 30 106 16 82 128 0.61 
64 44 F 2 y  N 130 80 154 46 19.39 30 0.7 151 30 104 17 80 124 0.6 
65 46 F 1 y  N 134 80 156 48 19.72 35 1 143 30 73 27 133 168 1.15 
66 46 F 2 y  Y 160 100 156 56 23.01 24 0.7 141 28 90 25 126 289 2.32 
67 48 M 2 y  N 128 78 160 56 21.87 26 0.8 165 30 112 23 115 160 0.88 
68 49 M 2 y  N 120 70 168 80 28.34 26 1 164 43 92 25 145 233 1.7 
69 51 M 1 y  Y 150 106 158 55 22.03 25 0.8 100 30 53 23 116 142 0.66 
70 52 M 2 y  Y 146 90 165 62 22.77 31 1.1 153 30 62 61 307 357 2.6 
71 55 M 1 y y N 110 70 167 65 23.3 30 0.8 175 37 114 24 126 322 0.99 
72 57 M 1  y Y 150 90 166 68 24.67 34 0.7 130 28 85 17 87 108 1.2 
73 55 F 1 y  N 124 80 162 56 21.33 34 0.9 142 40 78 24 120 182 0.79 
74 58 F 1  y N 130 80 160 58 22.65 36 0.8 164 31 104 28 140 170 1.45 
75 59 F 2 y  N 120 80 160 82 32.03 32 0.7 177 45 80 52 262 509 1.98 
76 54 F 2 y  N 120 70 160 56 21.87 27 0.8 166 30 114 22 111 182 0.72 
77 62 M 2 y  N 124 74 170 92 31.83 27 0.8 164 39 99 26 127 222 2.04 
78 64 M 1  y N 120 70 168 75 26.57 24 0.7 149 28 82 19 96 130 1.18 
79 61 F 2  y N 120 80 152 52 22.5 26 0.8 153 34 91 25 124 168 0.84 
80 62 F 1 y  N 120 76 156 60 24.65 32 0.9 188 36 115 36 186 275 1.37 
 
 
 
  
 
 
 
 
 
 
 
 
 
81 36 M 2 y N 126 76 166 55 19.95 32 0.9 151 26 108 17 86 128 0.6
82 36 M 1 y N 130 80 172 67 22.64 35 0.8 174 38 110 26 130 282 1.14
83 38 F 1 y y N 136 76 164 64 23.79 33 0.9 116 28 63 25 145 258 1.72
84 41 M 3 y N 120 80 160 48 18.75 32 1 114 25 70 18 96 164 1.48
85 41 M 2 y N 128 80 171 56 19.15 33 0.9 142 34 88 20 101 132 0.76
86 44 M 1 y N 120 76 169 62 21.7 33 0.8 169 52 90 28 136 323 1.88
87 46 M 2 y N 110 70 166 58 21.04 27 0.8 164 36 90 38 190 288 1.66
88 47 F 1 y Y 150 90 152 54 23.37 26 0.7 231 44 158 29 145 276 1.86
89 48 F 2 y Y 130 80 160 61 23.82 30 1.2 248 35 175 38 190 302 2.34
90 51 M 1 y N 110 72 170 67 23.18 30 0.8 152 36 100 16 82 165 0.76
91 52 M 1 y N 120 78 171 70 23.93 32 0.7 182 30 100 52 258 364 1.82
92 52 M 2 y N 126 76 166 75 27.21 38 0.8 163 28 89 46 232 302 1.92
93 54 M 2 y Y 120 80 170 62 21.45 35 0.9 116 54 47 15 65 93 0.93
94 55 M 1 y N 116 70 166 56 20.32 34 0.7 145 37 82 28 138 170 1.09
95 56 F 2 y Y 150 100 152 54 23.37 35 0.8 214 38 149 27 136 254 2.71
96 58 F 2 y N 120 80 150 65 28.88 33 0.7 156 28 101 27 133 176 1.22
97 58 F 1 y y N 126 76 148 64 29.21 26 0.8 174 32 92 50 248 323 1.68
98 62 M 1 y N 120 74 166 90 32.66 28 0.8 132 38 70 28 140 170 0.68
99 64 M 1 y N 112 70 166 98 35.56 30 1.1 170 35 110 27 125 210 1.42
100 65 F 1 y y N 128 80 165 90 33.06 31 0.7 187 33 100 54 272 366 1.09
 KEYS TO MASTER CHART 
 
 
Dur –   Duration  of  Diabetes 
 
OHA-  Oral  Hypoglycemic Agents 
 
Ins-      Insulin 
 
SHT-   Systemic Hypertension 
 
SBP-   Systolic Blood Pressure 
 
DBP-  Diastolic Blood Pressure 
 
Ht-      Height 
 
Wt-     Weight 
 
BMI-  Body Mass index 
 
Cr-     Creatinine, serum 
 
TC-    Total cholesterol 
 
fTG-   Fasting triglycerides 
 
ppTG- Postprandial triglycerides 
 
CIMT- Carotid intima-media thickness 
 
Y /y - yes 
 
N-  No 
